Stockreport

FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

SpringWorks Therapeutics, Inc. - common stock  (SWTX) 
Last springworks therapeutics, inc. - common stock earnings: 3/12 04:30 pm Check Earnings Report
PDF – PDUFA target action date of February 28, 2025 – – EU Marketing Authorization Application also validated by European Medicines Agency – STAMFORD, Conn., Aug. 28, 202 [Read more]